Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Anemia

7 Dec 2011

Abstract excerpt

Until recently, pediatric Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) was associated with an extremely poor outcome when treated with chemotherapy alone, and only modest survival benefits were obtained with the widespread use of hematopoietic stem cell transplantation (HSCT). The development of first-generation (imatinib) and second-generation (dasatinib and nilotinib) tyrosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22160058
DOI: 10.1182/asheducation-2011.1.361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic AnemiaPMID 22160058Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome‐positive adult acute lymphoblastic leukemiaSemantic proximity Read ↗

How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adultsSemantic proximity Read ↗

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in ChildhoodSemantic proximity Read ↗

Clinical screening for Ph-like ALL and the developing role of TKIs.Semantic proximity Read ↗

Advances in the Genetics and Therapy of Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Advances in the Genetics and Therapy of Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read ↗

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.